Dec 23, 2023 09:02 PM
https://blog.petrieflom.law.harvard.edu/...ew-viagra/
EXCERPTS: Spravato, the first FDA-approved psychedelic therapy, just outsold Viagra. Johnson & Johnson’s ketamine-based formulation generated $183 million in Q3, surpassing Pfizer’s erectile dysfunction (ED) drug, which earned $110 million over the same period. Remarkably, a therapeutic made from ketamine, once dismissed as a “club drug” or “horse tranquilizer,” now sells more than one of the most notable 21st-century pharmaceuticals.
Yet, these two drugs have more in common than meets the eye, and the path Spravato has taken looks strangely similar to that of Viagra. By looking at the journey traversed by Viagra over the past twenty years, we can predict where Spravato (and other psychedelic therapies) are headed.
[...] Spravato and Viagra are distinct pharmaceuticals, so we may not see an identical course for both. Yet, there are also some key similarities between the two that indicate the Spravato life cycle will closely resemble Viagra’s in the end. Both were serendipitously discovered as effective remedies for difficult-to-treat conditions. Both pioneered a new group of therapeutics and initially sold extremely well with limited competition. And, both drugs overcame stigma with clever ad campaigns and political support to ultimately sell very well in their early years.
The central message here is that recurrent structures manifest in the pharmaceutical industry, and those structures can be informative to foresee future patterns.... (MORE - missing details)
EXCERPTS: Spravato, the first FDA-approved psychedelic therapy, just outsold Viagra. Johnson & Johnson’s ketamine-based formulation generated $183 million in Q3, surpassing Pfizer’s erectile dysfunction (ED) drug, which earned $110 million over the same period. Remarkably, a therapeutic made from ketamine, once dismissed as a “club drug” or “horse tranquilizer,” now sells more than one of the most notable 21st-century pharmaceuticals.
Yet, these two drugs have more in common than meets the eye, and the path Spravato has taken looks strangely similar to that of Viagra. By looking at the journey traversed by Viagra over the past twenty years, we can predict where Spravato (and other psychedelic therapies) are headed.
[...] Spravato and Viagra are distinct pharmaceuticals, so we may not see an identical course for both. Yet, there are also some key similarities between the two that indicate the Spravato life cycle will closely resemble Viagra’s in the end. Both were serendipitously discovered as effective remedies for difficult-to-treat conditions. Both pioneered a new group of therapeutics and initially sold extremely well with limited competition. And, both drugs overcame stigma with clever ad campaigns and political support to ultimately sell very well in their early years.
The central message here is that recurrent structures manifest in the pharmaceutical industry, and those structures can be informative to foresee future patterns.... (MORE - missing details)